LSUHSC contributes to revealing targets to reduce racial disparity in prostate cancer deaths

July 29, 2009

New Orleans, LA - The latest findings of the North Carolina-Louisiana Prostate Cancer Project reveal potential new targets for reducing racial disparities in prostate cancer survival and highlight the importance of the health care delivery system. The study reports differences in physician trust, access to care, and continuity of care between African American and Caucasian men which result in advanced prostate cancer at the time of diagnosis and contribute to the higher death rate among African American men. The study is published in the early view issue of Cancer online July 27, 2009.

Study nurses conducted in depth in-home interviews with more than 1,000 North Carolina and Louisiana men age 50 and up, newly diagnosed with prostate cancer. Data in this manuscript were obtained from the interview and from medical record review.

This study examined health care system factors that may influence outcomes. System factors include availability of health care facilities, the services offered at those facilities, the systems in place to trigger appropriate utilization of those services, and clinician time pressures or encounter characteristics may impede their ability to fully address patient needs. Other factors such as provider bias, erroneous stereotypes or lack of understanding of minorities may also influence patient trust, health behaviors, and receptivity toward seeking or utilizing health care services.

"The lack of access to care, lack of a medical home and lack of a relationship with a medical provider may result in a delayed diagnosis that translates to advanced disease and higher rates of death from prostate cancer for African Americans," notes Elizabeth T. H. Fontham, DrPH, Dean of the School of Public Health at LSU Health Sciences Center New Orleans, who is the principal investigator of the Louisiana portion, and co- principal investigator of the entire study.

In this study, the stage at diagnosis of prostate cancer was similar between African American and Caucasian men, but African American men had more aggressive cancer as measured by Gleason score. Compared with African Americans, Caucasian men exhibited higher physician trust scores and a greater likelihood of reporting a physician office as their usual source of care, seeing the same physician at regular medical visits, and being screened for prostate cancer. African American men were less likely to report prostate cancer screening prior to diagnosis, and men without a prior history of screening were more likely to be diagnosed with advanced stage or high grade prostate cancer than men who reported a history of screening. "Importantly, no differences in prostate cancer stage at diagnosis were observed between men of either race when an established relationship with a healthcare provider existed," notes Elizabeth T. H. Fontham, DrPH, Dean of the School of Public Health at LSU Health Sciences Center New Orleans, who is the principal investigator of the Louisiana portion, and co- principal investigator of the entire study. "Through an ongoing relationship with their health care provider, patients' health status and risks are known, trust builds over time when consistent, high quality interactions between patients and providers take place, and patients are more likely to make informed decisions and receive more timely diagnosis and treatment."

According to the American Cancer Society, prostate cancer has the highest incidence of cancers among US men and is the second most deadly. The prostate cancer incidence rate among African Americans is 55% greater than among Caucasian men, and the African American death rate is two and a half times that of Caucasian men.

The researchers conclude that addressing components of how health care is delivered, including care continuity, has the potential to meaningfully address the mortality disparity observed for prostate cancer.

Funded by the Department of Defense, the North Carolina-Louisiana Prostate Cancer Project is a population-based study of individuals identified shortly after prostate cancer diagnosis designed to produce clinical data and identify racial disparities in prostate cancer, to help determine the best approach to reduce prostate cancer mortality.

Study authors include Dr. Fontham, William Carpenter, PhD, Research Assistant Professor of Health Policy and Management in the University of North Carolina Gillings School of Global Public Health, James Mohler, MD, Chair of the Department of Urology at Roswell Park Cancer Institute, principal investigator of the Consortium, and other researchers at these institutions.
-end-
LSU Health Sciences Center New Orleans educates the majority of Louisiana's health care professionals. The state's academic health leader, LSUHSC comprises a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, Schools of Allied Health Professions and Graduate Studies, as well as the only School of Nursing in Louisiana within an academic health center. LSUHSC faculty take care of patients in public and private hospitals and clinics throughout Louisiana. In the vanguard of biosciences research in a number of areas worldwide, LSUHSC faculty have made lifesaving discoveries and continue to work to prevent, treat, or cure disease. LSUHSC outreach programs span the state. www.twitter.com/LSUHSCHealth

Louisiana State University Health Sciences Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.